Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download Microsoft EdgeDownload Microsoft Edge
Press release

Result of Annual General Meeting

October 30, 2020

Oxford, U.K. 30 October 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that at its virtual Annual General Meeting (‘AGM’) held today at 2pm, all resolutions were duly passed. Results are set out below and the full text of the resolutions considered at the AGM are contained in the notice of AGM published on 06 October 2020 which is available on Sensyne’s website.

Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:

“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care.  In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.  

Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."

For information, full details of the votes received were as follows:

At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:

“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”

Press release

Result of Annual General Meeting

October 30, 2020

Oxford, U.K. 30 October 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that at its virtual Annual General Meeting (‘AGM’) held today at 2pm, all resolutions were duly passed. Results are set out below and the full text of the resolutions considered at the AGM are contained in the notice of AGM published on 06 October 2020 which is available on Sensyne’s website.

Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:

“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care.  In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.  

Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."

For information, full details of the votes received were as follows:

At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:

“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”

Press release

Result of Annual General Meeting

Result of Annual General Meeting

October 30, 2020

Oxford, U.K. 30 October 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that at its virtual Annual General Meeting (‘AGM’) held today at 2pm, all resolutions were duly passed. Results are set out below and the full text of the resolutions considered at the AGM are contained in the notice of AGM published on 06 October 2020 which is available on Sensyne’s website.

Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:

“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care.  In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.  

Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."

For information, full details of the votes received were as follows:

At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:

“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”

Press release

Result of Annual General Meeting

Result of Annual General Meeting

Oxford, U.K. 30 October 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that at its virtual Annual General Meeting (‘AGM’) held today at 2pm, all resolutions were duly passed. Results are set out below and the full text of the resolutions considered at the AGM are contained in the notice of AGM published on 06 October 2020 which is available on Sensyne’s website.

Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:

“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care.  In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.  

Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."

For information, full details of the votes received were as follows:

At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:

“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”

Arrange to meet us
Press release

Result of Annual General Meeting

October 30, 2020

Oxford, U.K. 30 October 2020: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the UK Clinical AI company, announces that at its virtual Annual General Meeting (‘AGM’) held today at 2pm, all resolutions were duly passed. Results are set out below and the full text of the resolutions considered at the AGM are contained in the notice of AGM published on 06 October 2020 which is available on Sensyne’s website.

Commenting at the event, Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health, said:

“Sensyne is in a strong position to apply its technology and expertise to help the life sciences and healthcare industries manage the short term challenges associated with coronavirus. Our software suite is being used to conduct clinical trials, monitor personal symptoms and disease progression and deliver remote patient care.  In the long term we are building a business that contributes to, and directly connects into, an increasingly digitised healthcare future.  

Most importantly we embody a better way to build technology companies – a way that recognises, respects and addresses the public, professional and institutional sensitivities related to ownership and privacy of highly personal healthcare data."

For information, full details of the votes received were as follows:

At the AGM the following statement was also read out by Sir Bruce Keogh, Non-Executive Chairman of Sensyne Health:

“During the course of the financial year, Lorimer Headley left the Board. He was an instrumental part of the successful IPO of Sensyne Health plc and subsequent commercial agreements, and prior to that provided a valuable contribution to the development of Drayson Technologies. On behalf of the Board, we would like to thank Mr Headley for his significant contribution to Sensyne.”